Bafna Pharmaceuticals Limited reported earnings results for the third quarter and nine months ended December 31, 2023. For the third quarter, the company reported sales was INR 284.42 million compared to INR 342.18 million a year ago. Revenue was INR 294.21 million compared to INR 361.45 million a year ago. Net loss was INR 29.42 million compared to net income of INR 29.95 million a year ago. Basic loss per share from continuing operations was INR 1.24 compared to basic earnings per share from continuing operations of INR 1.26 a year ago. Diluted loss per share from continuing operations was INR 1.24 compared to diluted earnings per share from continuing operations of INR 1.26 a year ago.
For the nine months, sales was INR 1,110.68 million compared to INR 731.06 million a year ago. Revenue was INR 1,140.75 million compared to INR 761.2 million a year ago. Net income was INR 58.93 million compared to INR 59.66 million a year ago. Basic earnings per share from continuing operations was INR 2.49 compared to INR 2.51 a year ago. Diluted earnings per share from continuing operations was INR 2.49 compared to INR 2.51 a year ago.